Fernandez JFD, et al. - In a real-world population, researchers evaluated the efficacy and safety of the Xience Prime everolimus-eluting stent (EES) in long coronary lesions. They assessed major adverse cardiac events (MACE; cardiac death, myocardial infarction, and target lesion revascularization) and stent thrombosis (ST) at 1, 12, and 24 months among consecutive patients (aged 64.8 ± 11.2 years, 77% men and 33% diabetics) in 29 tertiary hospitals with de novo > 24 mm lesions in vessels of 2.25–4 mm. The observed device success rate was 99.1%. The observed MACE and ST rates at 1, 12, and 24 months follow-up were 0.3, 2.1, and 5.4% and 0.2, 0.7, and 1.5%, respectively. In this prospective, multicenter registry, they found that the Xience Prime EES performed extremely well in long lesions, with a very low rate of both MACE and ST in a real-world population.